User login
Genotype-guided warfarin appears safer
Genotype-guided warfarin dosing is safer than clinically guided dosing for patients undergoing elective hip or knee arthroplasty, according to a study published in JAMA.
Investigators found that genotype-guided dosing reduced a patient’s combined risk of experiencing major bleeding, having an international normalized ratio (INR) of 4 or greater, and developing venous thromboembolism (VTE).
Death was also included in this combined endpoint, but there were no deaths in either dosing group.
“Physicians have been prescribing warfarin since the Eisenhower administration,” said study author Brian F. Gage, MD, of Washington University School of Medicine in St. Louis.
“It’s a widely used anticoagulant, but it causes more major adverse events than any other oral drug. Thousands of patients end up in the emergency department or hospital because of warfarin-induced bleeding, but we continue to prescribe it because it is highly effective, reversible, and inexpensive. So our goal is to make warfarin safer.”
With this in mind, Dr Gage and his colleagues set out to determine if genotype-guided dosing would be safer for patients starting warfarin because of elective hip or knee replacement.
The investigators noted that earlier studies of genotype-guided warfarin dosing had produced conflicting results. However, these studies were smaller and included fewer genetic variants than the current trial, known as GIFT.
The GIFT study included 1650 patients, age 65 and older. They were genotyped for the following polymorphisms: VKORC1-1639G>A, CYP2C9*2, CYP2C9*3, and CYP4F2 V433M.
Then, patients were randomized to clinically guided (n=789) or genotype-guided warfarin dosing (n=808) on days 1 through 11 of therapy and to a target INR of either 1.8 or 2.5. (Clinically guided dosing was based on standard factors such as age, height, and weight, while genotype-guided dosing was influenced by clinical factors plus the aforementioned genetic variants.)
Results
The primary endpoint was a combination of major bleeding, INR of 4 or greater, VTE, and death.
This endpoint was met by 10.8% (n=87) of patients in the genotype-guided group and 14.7% (n=116) of patients in the clinically guided warfarin group. The relative rate (RR) was 0.73 (P=0.02).
The incidence of major bleeding on days 1 to 30 was 0.2% (n=2) in the genotype-guided group and 1.0% (n=8) in the clinically guided group. The RR was 0.24 (P=0.06).
The proportion of patients with an INR of 4 or greater on days 1 to 30 was 6.9% (n=56) in the genotype-guided group and 9.8% (n=77) in the clinically guided group. The RR was 2.8 (P=0.04).
The incidence of VTE on days 1 to 60 was similar—4.1% (n=33) in the genotype-guided group and 4.8% the clinically guided group. The RR was 0.85 (P=0.48).
There were no deaths in either group (on days 1 to 30).
The investigators noted that this study has limitations. In particular, the benefits of genotype-guided dosing may differ when applied to patients of other ages or to general clinical practice.
The team also said additional research is needed to determine the cost-effectiveness of personalized warfarin dosing.
“Although genetic testing is more expensive than clinical dosing, the cost is falling,” Dr Gage said. “In our study, we estimated that genetic testing costs less than $200 per person, which is less than 1 month of a newer anticoagulant.”
Finally, the investigators said future studies should assess the impact of additional genetic variants.
“There are additional genetic variants that may help to guide warfarin dosing, especially among patients with African ancestry,” Dr Gage said. “In the future, we hope to quantify how these variants affect warfarin.” 
Genotype-guided warfarin dosing is safer than clinically guided dosing for patients undergoing elective hip or knee arthroplasty, according to a study published in JAMA.
Investigators found that genotype-guided dosing reduced a patient’s combined risk of experiencing major bleeding, having an international normalized ratio (INR) of 4 or greater, and developing venous thromboembolism (VTE).
Death was also included in this combined endpoint, but there were no deaths in either dosing group.
“Physicians have been prescribing warfarin since the Eisenhower administration,” said study author Brian F. Gage, MD, of Washington University School of Medicine in St. Louis.
“It’s a widely used anticoagulant, but it causes more major adverse events than any other oral drug. Thousands of patients end up in the emergency department or hospital because of warfarin-induced bleeding, but we continue to prescribe it because it is highly effective, reversible, and inexpensive. So our goal is to make warfarin safer.”
With this in mind, Dr Gage and his colleagues set out to determine if genotype-guided dosing would be safer for patients starting warfarin because of elective hip or knee replacement.
The investigators noted that earlier studies of genotype-guided warfarin dosing had produced conflicting results. However, these studies were smaller and included fewer genetic variants than the current trial, known as GIFT.
The GIFT study included 1650 patients, age 65 and older. They were genotyped for the following polymorphisms: VKORC1-1639G>A, CYP2C9*2, CYP2C9*3, and CYP4F2 V433M.
Then, patients were randomized to clinically guided (n=789) or genotype-guided warfarin dosing (n=808) on days 1 through 11 of therapy and to a target INR of either 1.8 or 2.5. (Clinically guided dosing was based on standard factors such as age, height, and weight, while genotype-guided dosing was influenced by clinical factors plus the aforementioned genetic variants.)
Results
The primary endpoint was a combination of major bleeding, INR of 4 or greater, VTE, and death.
This endpoint was met by 10.8% (n=87) of patients in the genotype-guided group and 14.7% (n=116) of patients in the clinically guided warfarin group. The relative rate (RR) was 0.73 (P=0.02).
The incidence of major bleeding on days 1 to 30 was 0.2% (n=2) in the genotype-guided group and 1.0% (n=8) in the clinically guided group. The RR was 0.24 (P=0.06).
The proportion of patients with an INR of 4 or greater on days 1 to 30 was 6.9% (n=56) in the genotype-guided group and 9.8% (n=77) in the clinically guided group. The RR was 2.8 (P=0.04).
The incidence of VTE on days 1 to 60 was similar—4.1% (n=33) in the genotype-guided group and 4.8% the clinically guided group. The RR was 0.85 (P=0.48).
There were no deaths in either group (on days 1 to 30).
The investigators noted that this study has limitations. In particular, the benefits of genotype-guided dosing may differ when applied to patients of other ages or to general clinical practice.
The team also said additional research is needed to determine the cost-effectiveness of personalized warfarin dosing.
“Although genetic testing is more expensive than clinical dosing, the cost is falling,” Dr Gage said. “In our study, we estimated that genetic testing costs less than $200 per person, which is less than 1 month of a newer anticoagulant.”
Finally, the investigators said future studies should assess the impact of additional genetic variants.
“There are additional genetic variants that may help to guide warfarin dosing, especially among patients with African ancestry,” Dr Gage said. “In the future, we hope to quantify how these variants affect warfarin.”
Genotype-guided warfarin dosing is safer than clinically guided dosing for patients undergoing elective hip or knee arthroplasty, according to a study published in JAMA.
Investigators found that genotype-guided dosing reduced a patient’s combined risk of experiencing major bleeding, having an international normalized ratio (INR) of 4 or greater, and developing venous thromboembolism (VTE).
Death was also included in this combined endpoint, but there were no deaths in either dosing group.
“Physicians have been prescribing warfarin since the Eisenhower administration,” said study author Brian F. Gage, MD, of Washington University School of Medicine in St. Louis.
“It’s a widely used anticoagulant, but it causes more major adverse events than any other oral drug. Thousands of patients end up in the emergency department or hospital because of warfarin-induced bleeding, but we continue to prescribe it because it is highly effective, reversible, and inexpensive. So our goal is to make warfarin safer.”
With this in mind, Dr Gage and his colleagues set out to determine if genotype-guided dosing would be safer for patients starting warfarin because of elective hip or knee replacement.
The investigators noted that earlier studies of genotype-guided warfarin dosing had produced conflicting results. However, these studies were smaller and included fewer genetic variants than the current trial, known as GIFT.
The GIFT study included 1650 patients, age 65 and older. They were genotyped for the following polymorphisms: VKORC1-1639G>A, CYP2C9*2, CYP2C9*3, and CYP4F2 V433M.
Then, patients were randomized to clinically guided (n=789) or genotype-guided warfarin dosing (n=808) on days 1 through 11 of therapy and to a target INR of either 1.8 or 2.5. (Clinically guided dosing was based on standard factors such as age, height, and weight, while genotype-guided dosing was influenced by clinical factors plus the aforementioned genetic variants.)
Results
The primary endpoint was a combination of major bleeding, INR of 4 or greater, VTE, and death.
This endpoint was met by 10.8% (n=87) of patients in the genotype-guided group and 14.7% (n=116) of patients in the clinically guided warfarin group. The relative rate (RR) was 0.73 (P=0.02).
The incidence of major bleeding on days 1 to 30 was 0.2% (n=2) in the genotype-guided group and 1.0% (n=8) in the clinically guided group. The RR was 0.24 (P=0.06).
The proportion of patients with an INR of 4 or greater on days 1 to 30 was 6.9% (n=56) in the genotype-guided group and 9.8% (n=77) in the clinically guided group. The RR was 2.8 (P=0.04).
The incidence of VTE on days 1 to 60 was similar—4.1% (n=33) in the genotype-guided group and 4.8% the clinically guided group. The RR was 0.85 (P=0.48).
There were no deaths in either group (on days 1 to 30).
The investigators noted that this study has limitations. In particular, the benefits of genotype-guided dosing may differ when applied to patients of other ages or to general clinical practice.
The team also said additional research is needed to determine the cost-effectiveness of personalized warfarin dosing.
“Although genetic testing is more expensive than clinical dosing, the cost is falling,” Dr Gage said. “In our study, we estimated that genetic testing costs less than $200 per person, which is less than 1 month of a newer anticoagulant.”
Finally, the investigators said future studies should assess the impact of additional genetic variants.
“There are additional genetic variants that may help to guide warfarin dosing, especially among patients with African ancestry,” Dr Gage said. “In the future, we hope to quantify how these variants affect warfarin.”
Representation in cancer clinical trials
ATLANTA—New research suggests some racial/ethnic minority groups are underrepresented in clinical trials for cancer patients in the US.
African-American and Hispanic patients were underrepresented in the trials studied, while Asian and non-Hispanic white patients were not.
Patients belonging to other racial/ethnic groups were not studied in detail.
The research also showed that elderly patients were less likely than other age groups to enroll in a cancer trial.
However, the percentage of elderly patients in the trials studied (36%) was more than double the percentage of elderly individuals in the US population (15.2%).
This research was presented at the 10th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved (abstract A26).
“Clinical trials are crucial in studying the effectiveness of new drugs and ultimately bringing them to the market to benefit patients,” said Narjust Duma, MD, of the Mayo Clinic in Rochester, Minnesota.
“However, many clinical trials lack appropriate representation of certain patient populations. As a result, the findings of a clinical trial might not be generalizable to all patients.”
Dr Duma and her colleagues analyzed enrollment data from all cancer therapeutic trials reported as completed on clinicaltrials.gov from 2003 to 2016. These trials included 55,689 subjects, and the racial/ethnic breakdown of the group was as follows:
- Non-Hispanic white—83%
- African-American—6%
- Asian—5.3%
- Hispanic—2.6%
- “Other”—2.4%.
According to the US Census Bureau, as of July 1, 2016, the estimated total US population was 323,127,516. The racial/ethnic breakdown of that population is as follows:
- White alone (excluding Hispanics/Latinos)—61.3%
- Hispanic/Latino*—17.8%
- Black/African-American alone—13.3%
- Asian alone—5.7%
- American Indian/Alaska Native—1.3%
- Native Hawaiian/Other Pacific Islander—0.2%
- Two or more races—2.6%.
Dr Duma and her colleagues said their study suggests African-American and Hispanic representation in cancer trials has declined in recent years, when compared to historical data from 1996 to 2002.
In the 1996-2002 period, African-Americans represented 9.2% of patients in cancer trials (vs 6% in 2003-2016), and Hispanics represented 3.1% (vs 2.6% in 2003-2016).
On the other hand, the recruitment of Asians in cancer trials has more than doubled, from 2% in the historical data to 5.3% in the current data.
The current study also showed that elderly patients (age 65 and older) represented 36% of the subjects enrolled in cancer trials. In comparison, 15.2% of the total US population is 65 or older.
Previous research suggested the elderly are often underrepresented in clinical trials, despite the fact that most cancer cases are diagnosed in individuals age 65 and older, according to the National Cancer Institute’s Surveillance, Epidemiology and End Results database.
Dr Duma said the increasing use of genetic information in clinical trials may be decreasing the numbers of ethnic minorities and elderly patients. In recent years, researchers have sought to study drugs that treat cancers by targeting certain mutations. In order to identify the patients who are most likely to respond to the drugs, many trials now require molecular testing of tumors.
“This is leading to significant advances,” Dr Duma said. “However, it is vastly more expensive to run these trials, often leaving a limited budget to recruit patients or do outreach to the elderly or minorities.”
“Also, this type of testing can only be conducted at the major cancer centers. The mid-sized, regional hospitals are excluded because they don’t have the capacity, and, sadly, this leaves us farther away from these populations.”
Dr Duma added that cultural biases may also make minorities less likely to enroll in clinical trials. Previous research has indicated that members of certain minority groups may be less likely to trust healthcare providers.
Language barriers may also be a factor for minority patients, and the elderly may be dissuaded by difficulty in traveling to and from major cancer centers, Dr Duma noted.
She identified a few potential ways to narrow the gap of participation in clinical trials:
- Increase clinical trial partnerships between major cancer centers and satellite hospitals. Dr Duma suggested that patients could be enrolled at their local hospital and undergo treatment there, while data could be sent to the partnering cancer center.
- Targeted interventions, such as Spanish interpreters, could be used to help enroll minority patients in clinical trials.
- Healthcare providers should be mindful of the need to enroll more patients from underrepresented populations and should be willing to discuss risks and benefits with patients.
Dr Duma said the main limitation of this study is that race and ethnicity are generally self-reported, which could lead to some inconsistencies in data.
*The US Census Bureau notes that Hispanics may be of any race, so they are also included in applicable race categories.
ATLANTA—New research suggests some racial/ethnic minority groups are underrepresented in clinical trials for cancer patients in the US.
African-American and Hispanic patients were underrepresented in the trials studied, while Asian and non-Hispanic white patients were not.
Patients belonging to other racial/ethnic groups were not studied in detail.
The research also showed that elderly patients were less likely than other age groups to enroll in a cancer trial.
However, the percentage of elderly patients in the trials studied (36%) was more than double the percentage of elderly individuals in the US population (15.2%).
This research was presented at the 10th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved (abstract A26).
“Clinical trials are crucial in studying the effectiveness of new drugs and ultimately bringing them to the market to benefit patients,” said Narjust Duma, MD, of the Mayo Clinic in Rochester, Minnesota.
“However, many clinical trials lack appropriate representation of certain patient populations. As a result, the findings of a clinical trial might not be generalizable to all patients.”
Dr Duma and her colleagues analyzed enrollment data from all cancer therapeutic trials reported as completed on clinicaltrials.gov from 2003 to 2016. These trials included 55,689 subjects, and the racial/ethnic breakdown of the group was as follows:
- Non-Hispanic white—83%
- African-American—6%
- Asian—5.3%
- Hispanic—2.6%
- “Other”—2.4%.
According to the US Census Bureau, as of July 1, 2016, the estimated total US population was 323,127,516. The racial/ethnic breakdown of that population is as follows:
- White alone (excluding Hispanics/Latinos)—61.3%
- Hispanic/Latino*—17.8%
- Black/African-American alone—13.3%
- Asian alone—5.7%
- American Indian/Alaska Native—1.3%
- Native Hawaiian/Other Pacific Islander—0.2%
- Two or more races—2.6%.
Dr Duma and her colleagues said their study suggests African-American and Hispanic representation in cancer trials has declined in recent years, when compared to historical data from 1996 to 2002.
In the 1996-2002 period, African-Americans represented 9.2% of patients in cancer trials (vs 6% in 2003-2016), and Hispanics represented 3.1% (vs 2.6% in 2003-2016).
On the other hand, the recruitment of Asians in cancer trials has more than doubled, from 2% in the historical data to 5.3% in the current data.
The current study also showed that elderly patients (age 65 and older) represented 36% of the subjects enrolled in cancer trials. In comparison, 15.2% of the total US population is 65 or older.
Previous research suggested the elderly are often underrepresented in clinical trials, despite the fact that most cancer cases are diagnosed in individuals age 65 and older, according to the National Cancer Institute’s Surveillance, Epidemiology and End Results database.
Dr Duma said the increasing use of genetic information in clinical trials may be decreasing the numbers of ethnic minorities and elderly patients. In recent years, researchers have sought to study drugs that treat cancers by targeting certain mutations. In order to identify the patients who are most likely to respond to the drugs, many trials now require molecular testing of tumors.
“This is leading to significant advances,” Dr Duma said. “However, it is vastly more expensive to run these trials, often leaving a limited budget to recruit patients or do outreach to the elderly or minorities.”
“Also, this type of testing can only be conducted at the major cancer centers. The mid-sized, regional hospitals are excluded because they don’t have the capacity, and, sadly, this leaves us farther away from these populations.”
Dr Duma added that cultural biases may also make minorities less likely to enroll in clinical trials. Previous research has indicated that members of certain minority groups may be less likely to trust healthcare providers.
Language barriers may also be a factor for minority patients, and the elderly may be dissuaded by difficulty in traveling to and from major cancer centers, Dr Duma noted.
She identified a few potential ways to narrow the gap of participation in clinical trials:
- Increase clinical trial partnerships between major cancer centers and satellite hospitals. Dr Duma suggested that patients could be enrolled at their local hospital and undergo treatment there, while data could be sent to the partnering cancer center.
- Targeted interventions, such as Spanish interpreters, could be used to help enroll minority patients in clinical trials.
- Healthcare providers should be mindful of the need to enroll more patients from underrepresented populations and should be willing to discuss risks and benefits with patients.
Dr Duma said the main limitation of this study is that race and ethnicity are generally self-reported, which could lead to some inconsistencies in data.
*The US Census Bureau notes that Hispanics may be of any race, so they are also included in applicable race categories.
ATLANTA—New research suggests some racial/ethnic minority groups are underrepresented in clinical trials for cancer patients in the US.
African-American and Hispanic patients were underrepresented in the trials studied, while Asian and non-Hispanic white patients were not.
Patients belonging to other racial/ethnic groups were not studied in detail.
The research also showed that elderly patients were less likely than other age groups to enroll in a cancer trial.
However, the percentage of elderly patients in the trials studied (36%) was more than double the percentage of elderly individuals in the US population (15.2%).
This research was presented at the 10th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved (abstract A26).
“Clinical trials are crucial in studying the effectiveness of new drugs and ultimately bringing them to the market to benefit patients,” said Narjust Duma, MD, of the Mayo Clinic in Rochester, Minnesota.
“However, many clinical trials lack appropriate representation of certain patient populations. As a result, the findings of a clinical trial might not be generalizable to all patients.”
Dr Duma and her colleagues analyzed enrollment data from all cancer therapeutic trials reported as completed on clinicaltrials.gov from 2003 to 2016. These trials included 55,689 subjects, and the racial/ethnic breakdown of the group was as follows:
- Non-Hispanic white—83%
- African-American—6%
- Asian—5.3%
- Hispanic—2.6%
- “Other”—2.4%.
According to the US Census Bureau, as of July 1, 2016, the estimated total US population was 323,127,516. The racial/ethnic breakdown of that population is as follows:
- White alone (excluding Hispanics/Latinos)—61.3%
- Hispanic/Latino*—17.8%
- Black/African-American alone—13.3%
- Asian alone—5.7%
- American Indian/Alaska Native—1.3%
- Native Hawaiian/Other Pacific Islander—0.2%
- Two or more races—2.6%.
Dr Duma and her colleagues said their study suggests African-American and Hispanic representation in cancer trials has declined in recent years, when compared to historical data from 1996 to 2002.
In the 1996-2002 period, African-Americans represented 9.2% of patients in cancer trials (vs 6% in 2003-2016), and Hispanics represented 3.1% (vs 2.6% in 2003-2016).
On the other hand, the recruitment of Asians in cancer trials has more than doubled, from 2% in the historical data to 5.3% in the current data.
The current study also showed that elderly patients (age 65 and older) represented 36% of the subjects enrolled in cancer trials. In comparison, 15.2% of the total US population is 65 or older.
Previous research suggested the elderly are often underrepresented in clinical trials, despite the fact that most cancer cases are diagnosed in individuals age 65 and older, according to the National Cancer Institute’s Surveillance, Epidemiology and End Results database.
Dr Duma said the increasing use of genetic information in clinical trials may be decreasing the numbers of ethnic minorities and elderly patients. In recent years, researchers have sought to study drugs that treat cancers by targeting certain mutations. In order to identify the patients who are most likely to respond to the drugs, many trials now require molecular testing of tumors.
“This is leading to significant advances,” Dr Duma said. “However, it is vastly more expensive to run these trials, often leaving a limited budget to recruit patients or do outreach to the elderly or minorities.”
“Also, this type of testing can only be conducted at the major cancer centers. The mid-sized, regional hospitals are excluded because they don’t have the capacity, and, sadly, this leaves us farther away from these populations.”
Dr Duma added that cultural biases may also make minorities less likely to enroll in clinical trials. Previous research has indicated that members of certain minority groups may be less likely to trust healthcare providers.
Language barriers may also be a factor for minority patients, and the elderly may be dissuaded by difficulty in traveling to and from major cancer centers, Dr Duma noted.
She identified a few potential ways to narrow the gap of participation in clinical trials:
- Increase clinical trial partnerships between major cancer centers and satellite hospitals. Dr Duma suggested that patients could be enrolled at their local hospital and undergo treatment there, while data could be sent to the partnering cancer center.
- Targeted interventions, such as Spanish interpreters, could be used to help enroll minority patients in clinical trials.
- Healthcare providers should be mindful of the need to enroll more patients from underrepresented populations and should be willing to discuss risks and benefits with patients.
Dr Duma said the main limitation of this study is that race and ethnicity are generally self-reported, which could lead to some inconsistencies in data.
*The US Census Bureau notes that Hispanics may be of any race, so they are also included in applicable race categories.
Dyslipidemia: Assessment and Treatment of Cardiovascular Risk: Applying 2016 ACC Recommendations
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
ACS weighs in on surgeon workforce bill
ACS weighs in on surgeon workforce bill
The American College of Surgeons (ACS) submitted a statement for the record (available at facs.org/~/media/files/email/091417_workforce.ashx) September 14 to the U.S. House Committee on Energy and Commerce regarding its hearing on Supporting Tomorrow’s Health Providers: Examining Workforce Programs under the Public Health Service Act. The statement emphasizes that building a solid foundation of accurate and actionable workforce data is critical to making rational, informed decisions for building an optimal health care workforce. The ACS reiterates its support for the Ensuring Access to General Surgery Act of 2017 (H.R. 2906/ S.1351), sponsored by Reps. Larry Bucshon, MD, FACS (R-IN), and Ami Bera, MD (D-CA), and Sens. Charles Grassley (R-IA) and Brian Schatz (D-HI). This legislation would direct the Secretary of the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration, to conduct a study to define and identify general surgery workforce shortage areas. Additionally, it would grant the Secretary the authority to provide a general surgery shortage area designation.
The ACS maintains that a shortage of general surgeons is a critical component of the nation’s health care workforce crisis. Consequently, the ACS is urging policymakers to recognize through the designation of a formal surgical shortage area that only surgeons are uniquely trained and qualified to provide certain necessary, lifesaving procedures. Surgeons play a pivotal role in the community-based health care system, but unlike other key community providers, surgery has no official shortage area designation.
The ACS encourages Fellows to contact their members of Congress through SurgeonsVoice (member login required) at www.surgeonsvoice.org to urge them to sign on in support of this legislation. For more information about surgical workforce shortage legislation, contact Carrie Zlatos, ACS Senior Congressional Lobbyist, at [email protected] or 202-672-1508.
ACS weighs in on surgeon workforce bill
The American College of Surgeons (ACS) submitted a statement for the record (available at facs.org/~/media/files/email/091417_workforce.ashx) September 14 to the U.S. House Committee on Energy and Commerce regarding its hearing on Supporting Tomorrow’s Health Providers: Examining Workforce Programs under the Public Health Service Act. The statement emphasizes that building a solid foundation of accurate and actionable workforce data is critical to making rational, informed decisions for building an optimal health care workforce. The ACS reiterates its support for the Ensuring Access to General Surgery Act of 2017 (H.R. 2906/ S.1351), sponsored by Reps. Larry Bucshon, MD, FACS (R-IN), and Ami Bera, MD (D-CA), and Sens. Charles Grassley (R-IA) and Brian Schatz (D-HI). This legislation would direct the Secretary of the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration, to conduct a study to define and identify general surgery workforce shortage areas. Additionally, it would grant the Secretary the authority to provide a general surgery shortage area designation.
The ACS maintains that a shortage of general surgeons is a critical component of the nation’s health care workforce crisis. Consequently, the ACS is urging policymakers to recognize through the designation of a formal surgical shortage area that only surgeons are uniquely trained and qualified to provide certain necessary, lifesaving procedures. Surgeons play a pivotal role in the community-based health care system, but unlike other key community providers, surgery has no official shortage area designation.
The ACS encourages Fellows to contact their members of Congress through SurgeonsVoice (member login required) at www.surgeonsvoice.org to urge them to sign on in support of this legislation. For more information about surgical workforce shortage legislation, contact Carrie Zlatos, ACS Senior Congressional Lobbyist, at [email protected] or 202-672-1508.
ACS weighs in on surgeon workforce bill
The American College of Surgeons (ACS) submitted a statement for the record (available at facs.org/~/media/files/email/091417_workforce.ashx) September 14 to the U.S. House Committee on Energy and Commerce regarding its hearing on Supporting Tomorrow’s Health Providers: Examining Workforce Programs under the Public Health Service Act. The statement emphasizes that building a solid foundation of accurate and actionable workforce data is critical to making rational, informed decisions for building an optimal health care workforce. The ACS reiterates its support for the Ensuring Access to General Surgery Act of 2017 (H.R. 2906/ S.1351), sponsored by Reps. Larry Bucshon, MD, FACS (R-IN), and Ami Bera, MD (D-CA), and Sens. Charles Grassley (R-IA) and Brian Schatz (D-HI). This legislation would direct the Secretary of the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration, to conduct a study to define and identify general surgery workforce shortage areas. Additionally, it would grant the Secretary the authority to provide a general surgery shortage area designation.
The ACS maintains that a shortage of general surgeons is a critical component of the nation’s health care workforce crisis. Consequently, the ACS is urging policymakers to recognize through the designation of a formal surgical shortage area that only surgeons are uniquely trained and qualified to provide certain necessary, lifesaving procedures. Surgeons play a pivotal role in the community-based health care system, but unlike other key community providers, surgery has no official shortage area designation.
The ACS encourages Fellows to contact their members of Congress through SurgeonsVoice (member login required) at www.surgeonsvoice.org to urge them to sign on in support of this legislation. For more information about surgical workforce shortage legislation, contact Carrie Zlatos, ACS Senior Congressional Lobbyist, at [email protected] or 202-672-1508.
Advantages of In-office Hysteroscopy in the Diagnosis of Abnormal Uterine Bleeding with Endosee
Click Here to Read the Supplement.
Topics include:
- The Endosee Office Procedure
- Patient Case Studies
- Advantages of Endosee Over Traditional Office Hysteroscopy
Dr. Ethan Goldstein, MD
Director of the Robotic
and Minimally Invasive Surgery Program
Detroit Medical Center’s Huron Valley-Sinai Hospital
Detroit, Michigan
Click Here to Read the Supplement.
Click Here to Read the Supplement.
Topics include:
- The Endosee Office Procedure
- Patient Case Studies
- Advantages of Endosee Over Traditional Office Hysteroscopy
Dr. Ethan Goldstein, MD
Director of the Robotic
and Minimally Invasive Surgery Program
Detroit Medical Center’s Huron Valley-Sinai Hospital
Detroit, Michigan
Click Here to Read the Supplement.
Click Here to Read the Supplement.
Topics include:
- The Endosee Office Procedure
- Patient Case Studies
- Advantages of Endosee Over Traditional Office Hysteroscopy
Dr. Ethan Goldstein, MD
Director of the Robotic
and Minimally Invasive Surgery Program
Detroit Medical Center’s Huron Valley-Sinai Hospital
Detroit, Michigan
Click Here to Read the Supplement.
Sleep Duration Affects Likelihood of Insomnia and Depression Remission
BOSTON—Objective sleep duration moderates the probability of remission among patients with comorbid depression and insomnia, according to research presented at the 31st Annual Meeting of the Associated Professional Sleep Societies. Sleep durations of greater than five to six hours increase the likelihood that these patients will achieve insomnia remission with cognitive behavioral therapy for insomnia (CBT-I), but do not affect the likelihood of depression remission. Sleep durations of seven or more hours optimize the likelihood of insomnia remission and depression remission in response to CBT-I.
In a 2015 consensus statement, the Sleep Research Society recommended seven or more hours of sleep per night for adults younger than 60. Studies indicate that sleep durations of less than five hours and less than six hours are associated with increased morbidity and poor treatment response among patients with insomnia. “We wanted to know what [sleep-duration] cutoffs … might be better predictors of eventual insomnia and depression remission through treatment,” said Jack Edinger, PhD, Professor of Medicine at National Jewish Health in Denver. 
An Analysis of the TRIAD Study
Dr. Edinger and colleagues conducted a secondary analysis of the TRIAD study, which examined whether combined treatment of depression and insomnia improves depression and sleep outcomes in participants with both disorders. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders (4th ed.) criteria for major depression and primary insomnia, had a Hamilton Rating Scale for Depression (HAMD-17) score of 16 or greater, and had an Insomnia Severity Index (ISI) score of 11 or greater. People who had had psychotherapy in the previous four months, or had failed or could not tolerate previous adequate trials of the study medications, were excluded. Participants completed one night of baseline polysomnography before entering the treatment phase of the study.
The study population included 104 participants (75 women) with a mean age of 47. Mean baseline HAMD-17 score was 22, and mean baseline ISI score was 20.6. All participants received antidepressant medication (ie, citalopram, sertraline, or venlafaxine). Patients were randomized to CBT-I or sham (ie, a pseudodesensitization condition with sleep education). The investigators assessed participants biweekly with the HAMD-17 and the ISI. The treatment period lasted for 16 weeks.
CBT-I Provided Benefits
Participants with five or more hours of sleep were more likely to respond to CBT-I than participants with fewer than five hours of sleep. Among participants with sleep duration of five or more hours, insomnia remission was more likely with CBT-I than with the control condition. The five-hour cutoff had no association with depression remission.
Among participants with six or more hours of sleep, those who received CBT-I were more likely to achieve insomnia remission than controls. The six-hour cutoff did not affect the likelihood of depression remission, however.
Among participants with seven or more hours of sleep, those randomized to CBT-I were more likely to achieve insomnia remission and depression remission than controls.
“More research is needed to determine how best to achieve depression remission in those patients with less than seven hours of objective sleep duration prior to starting treatment,” Dr. Edinger concluded.
—Erik Greb
Suggested Reading
Bathgate CJ, Edinger JD, Krystal AD. Insomnia patients with objective short sleep duration have a blunted response to cognitive behavioral therapy for insomnia. Sleep. 2017;40(1).
Vgontzas AN, Liao D, Bixler EO, et al. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-497.
Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: A joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38(6):843-844.
BOSTON—Objective sleep duration moderates the probability of remission among patients with comorbid depression and insomnia, according to research presented at the 31st Annual Meeting of the Associated Professional Sleep Societies. Sleep durations of greater than five to six hours increase the likelihood that these patients will achieve insomnia remission with cognitive behavioral therapy for insomnia (CBT-I), but do not affect the likelihood of depression remission. Sleep durations of seven or more hours optimize the likelihood of insomnia remission and depression remission in response to CBT-I.
In a 2015 consensus statement, the Sleep Research Society recommended seven or more hours of sleep per night for adults younger than 60. Studies indicate that sleep durations of less than five hours and less than six hours are associated with increased morbidity and poor treatment response among patients with insomnia. “We wanted to know what [sleep-duration] cutoffs … might be better predictors of eventual insomnia and depression remission through treatment,” said Jack Edinger, PhD, Professor of Medicine at National Jewish Health in Denver.
An Analysis of the TRIAD Study
Dr. Edinger and colleagues conducted a secondary analysis of the TRIAD study, which examined whether combined treatment of depression and insomnia improves depression and sleep outcomes in participants with both disorders. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders (4th ed.) criteria for major depression and primary insomnia, had a Hamilton Rating Scale for Depression (HAMD-17) score of 16 or greater, and had an Insomnia Severity Index (ISI) score of 11 or greater. People who had had psychotherapy in the previous four months, or had failed or could not tolerate previous adequate trials of the study medications, were excluded. Participants completed one night of baseline polysomnography before entering the treatment phase of the study.
The study population included 104 participants (75 women) with a mean age of 47. Mean baseline HAMD-17 score was 22, and mean baseline ISI score was 20.6. All participants received antidepressant medication (ie, citalopram, sertraline, or venlafaxine). Patients were randomized to CBT-I or sham (ie, a pseudodesensitization condition with sleep education). The investigators assessed participants biweekly with the HAMD-17 and the ISI. The treatment period lasted for 16 weeks.
CBT-I Provided Benefits
Participants with five or more hours of sleep were more likely to respond to CBT-I than participants with fewer than five hours of sleep. Among participants with sleep duration of five or more hours, insomnia remission was more likely with CBT-I than with the control condition. The five-hour cutoff had no association with depression remission.
Among participants with six or more hours of sleep, those who received CBT-I were more likely to achieve insomnia remission than controls. The six-hour cutoff did not affect the likelihood of depression remission, however.
Among participants with seven or more hours of sleep, those randomized to CBT-I were more likely to achieve insomnia remission and depression remission than controls.
“More research is needed to determine how best to achieve depression remission in those patients with less than seven hours of objective sleep duration prior to starting treatment,” Dr. Edinger concluded.
—Erik Greb
Suggested Reading
Bathgate CJ, Edinger JD, Krystal AD. Insomnia patients with objective short sleep duration have a blunted response to cognitive behavioral therapy for insomnia. Sleep. 2017;40(1).
Vgontzas AN, Liao D, Bixler EO, et al. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-497.
Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: A joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38(6):843-844.
BOSTON—Objective sleep duration moderates the probability of remission among patients with comorbid depression and insomnia, according to research presented at the 31st Annual Meeting of the Associated Professional Sleep Societies. Sleep durations of greater than five to six hours increase the likelihood that these patients will achieve insomnia remission with cognitive behavioral therapy for insomnia (CBT-I), but do not affect the likelihood of depression remission. Sleep durations of seven or more hours optimize the likelihood of insomnia remission and depression remission in response to CBT-I.
In a 2015 consensus statement, the Sleep Research Society recommended seven or more hours of sleep per night for adults younger than 60. Studies indicate that sleep durations of less than five hours and less than six hours are associated with increased morbidity and poor treatment response among patients with insomnia. “We wanted to know what [sleep-duration] cutoffs … might be better predictors of eventual insomnia and depression remission through treatment,” said Jack Edinger, PhD, Professor of Medicine at National Jewish Health in Denver.
An Analysis of the TRIAD Study
Dr. Edinger and colleagues conducted a secondary analysis of the TRIAD study, which examined whether combined treatment of depression and insomnia improves depression and sleep outcomes in participants with both disorders. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders (4th ed.) criteria for major depression and primary insomnia, had a Hamilton Rating Scale for Depression (HAMD-17) score of 16 or greater, and had an Insomnia Severity Index (ISI) score of 11 or greater. People who had had psychotherapy in the previous four months, or had failed or could not tolerate previous adequate trials of the study medications, were excluded. Participants completed one night of baseline polysomnography before entering the treatment phase of the study.
The study population included 104 participants (75 women) with a mean age of 47. Mean baseline HAMD-17 score was 22, and mean baseline ISI score was 20.6. All participants received antidepressant medication (ie, citalopram, sertraline, or venlafaxine). Patients were randomized to CBT-I or sham (ie, a pseudodesensitization condition with sleep education). The investigators assessed participants biweekly with the HAMD-17 and the ISI. The treatment period lasted for 16 weeks.
CBT-I Provided Benefits
Participants with five or more hours of sleep were more likely to respond to CBT-I than participants with fewer than five hours of sleep. Among participants with sleep duration of five or more hours, insomnia remission was more likely with CBT-I than with the control condition. The five-hour cutoff had no association with depression remission.
Among participants with six or more hours of sleep, those who received CBT-I were more likely to achieve insomnia remission than controls. The six-hour cutoff did not affect the likelihood of depression remission, however.
Among participants with seven or more hours of sleep, those randomized to CBT-I were more likely to achieve insomnia remission and depression remission than controls.
“More research is needed to determine how best to achieve depression remission in those patients with less than seven hours of objective sleep duration prior to starting treatment,” Dr. Edinger concluded.
—Erik Greb
Suggested Reading
Bathgate CJ, Edinger JD, Krystal AD. Insomnia patients with objective short sleep duration have a blunted response to cognitive behavioral therapy for insomnia. Sleep. 2017;40(1).
Vgontzas AN, Liao D, Bixler EO, et al. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-497.
Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: A joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38(6):843-844.
The many faces of dermoid
A) Dermoid plug CORRECT
The most common appearance of an ovarian dermoid is a cystic lesion with a focal echogenic nodule protruding into the cyst (Rokitansky nodule).1
B) Tip-of-the-iceberg sign INCORRECT
The next most common appearance of an ovarian dermoid is a focal or diffuse hyperechoic mass with areas of sound attenuation from the sebaceous material and hair, often called the tip-of-the-iceberg sign.1
C) Dot-dash pattern INCORRECT
The 3rd most common appearance of an ovarian dermoid is a cystic lesion with multiple thin echogenic bands (lines and dots) that visualize hair floating within the cyst.1
D) Fat-fluid level INCORRECT
The 4th most common appearance of an ovarian dermoid is a result of the echogenic sebum and hypoechoic serous fluid causing a fat-fluid level.1
- Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas: tumor types and imaging characteristics. RadioGraphics. 2001;21(2):475–490.
Dr. Kanmaniraja is Assistant Professor and Chief, Division of Abdominal Imaging, Department of Radiology, University of Florida College of Medicine-Jacksonville.
Dr. Kaunitz is University of Florida Term Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville. He is Medical Director and Director of Menopause and Gynecologic Ultrasound Services at UF Women's Health Specialists-Emerson. He also serves on the OBG Management Board of Editors.
The authors report no additional financial relationships relevant to this quiz.
Dr. Kanmaniraja is Assistant Professor and Chief, Division of Abdominal Imaging, Department of Radiology, University of Florida College of Medicine-Jacksonville.
Dr. Kaunitz is University of Florida Term Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville. He is Medical Director and Director of Menopause and Gynecologic Ultrasound Services at UF Women's Health Specialists-Emerson. He also serves on the OBG Management Board of Editors.
The authors report no additional financial relationships relevant to this quiz.
Dr. Kanmaniraja is Assistant Professor and Chief, Division of Abdominal Imaging, Department of Radiology, University of Florida College of Medicine-Jacksonville.
Dr. Kaunitz is University of Florida Term Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville. He is Medical Director and Director of Menopause and Gynecologic Ultrasound Services at UF Women's Health Specialists-Emerson. He also serves on the OBG Management Board of Editors.
The authors report no additional financial relationships relevant to this quiz.
A) Dermoid plug CORRECT
The most common appearance of an ovarian dermoid is a cystic lesion with a focal echogenic nodule protruding into the cyst (Rokitansky nodule).1
B) Tip-of-the-iceberg sign INCORRECT
The next most common appearance of an ovarian dermoid is a focal or diffuse hyperechoic mass with areas of sound attenuation from the sebaceous material and hair, often called the tip-of-the-iceberg sign.1
C) Dot-dash pattern INCORRECT
The 3rd most common appearance of an ovarian dermoid is a cystic lesion with multiple thin echogenic bands (lines and dots) that visualize hair floating within the cyst.1
D) Fat-fluid level INCORRECT
The 4th most common appearance of an ovarian dermoid is a result of the echogenic sebum and hypoechoic serous fluid causing a fat-fluid level.1
A) Dermoid plug CORRECT
The most common appearance of an ovarian dermoid is a cystic lesion with a focal echogenic nodule protruding into the cyst (Rokitansky nodule).1
B) Tip-of-the-iceberg sign INCORRECT
The next most common appearance of an ovarian dermoid is a focal or diffuse hyperechoic mass with areas of sound attenuation from the sebaceous material and hair, often called the tip-of-the-iceberg sign.1
C) Dot-dash pattern INCORRECT
The 3rd most common appearance of an ovarian dermoid is a cystic lesion with multiple thin echogenic bands (lines and dots) that visualize hair floating within the cyst.1
D) Fat-fluid level INCORRECT
The 4th most common appearance of an ovarian dermoid is a result of the echogenic sebum and hypoechoic serous fluid causing a fat-fluid level.1
- Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas: tumor types and imaging characteristics. RadioGraphics. 2001;21(2):475–490.
- Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas: tumor types and imaging characteristics. RadioGraphics. 2001;21(2):475–490.
A 49-year-old woman with pelvic discomfort presents to her gynecologist. Physical exam suggests unilateral adnexal fullness; the gynecologist orders transvaginal pelvic ultrasonography.
How Does Cognitive Demand Affect Mobility in MS?
Patients with multiple sclerosis (MS) with an Expanded Disability Status Scale (EDSS) score between 4 and 6 have significantly slower times on the Timed Up and Go (TUG) test with the addition of a simple cognitive task, according to research published in the July–August issue of International Journal of MS Care. This reduction in performance “might have implications for a person’s more complex everyday activities,” the researchers said.
Patients with MS may develop cognitive impairment (eg, reduced processing speed or working memory), but standard cognitive assessments overlook how cognitive function affects mobility. To assess how the addition of a cognitive task affects mobility in patients with MS, George H. Kraft, MD, Emeritus Alvord Professor of MS Research at the University of Washington in Seattle, and colleagues conducted a study that included 52 adults with MS and 57 healthy controls. Participants had a mean age of about 47, and most were women. 
The participants completed three versions of the TUG test: the standard test, the test plus reciting the alphabet, and the test plus subtracting from a number by threes. Times to complete the tests were compared between controls and three groups of participants with MS—those with an EDSS score of 0–3.5 (n = 26), those with an EDSS score of 4.0–5.5 (n = 11), and those with an EDSS score of 6 (n = 15).
Overall mean times for the four groups were 8.0, 8.2, 11.1, and 11.6 seconds, respectively. Controls did not differ from people with MS without mobility problems (ie, those with an EDSS score of 0–3.5), but did differ from the other two groups.
“Individuals with MS and no mobility problems have ... very little increase in time due to the addition of cognitive tasks to the TUG test. The two more severe groups perform similarly to each other, with a steeper increase in time to perform the test when the cognitive demand increases,” the researchers said. “Although we cannot automatically generalize the results to more complex everyday activities, such as walking or driving a car while talking on a cell phone, the reduction in performance is an important issue that should be discussed with the patient and his or her caregiver.”
—Jake Remaly
Suggested Reading
Ciol MA, Matsuda PN, Khurana SR, et al. Effect of cognitive demand on functional mobility in ambulatory individuals with multiple sclerosis. Int J MS Care. 2017;19(4):217-224.
Patients with multiple sclerosis (MS) with an Expanded Disability Status Scale (EDSS) score between 4 and 6 have significantly slower times on the Timed Up and Go (TUG) test with the addition of a simple cognitive task, according to research published in the July–August issue of International Journal of MS Care. This reduction in performance “might have implications for a person’s more complex everyday activities,” the researchers said.
Patients with MS may develop cognitive impairment (eg, reduced processing speed or working memory), but standard cognitive assessments overlook how cognitive function affects mobility. To assess how the addition of a cognitive task affects mobility in patients with MS, George H. Kraft, MD, Emeritus Alvord Professor of MS Research at the University of Washington in Seattle, and colleagues conducted a study that included 52 adults with MS and 57 healthy controls. Participants had a mean age of about 47, and most were women.
The participants completed three versions of the TUG test: the standard test, the test plus reciting the alphabet, and the test plus subtracting from a number by threes. Times to complete the tests were compared between controls and three groups of participants with MS—those with an EDSS score of 0–3.5 (n = 26), those with an EDSS score of 4.0–5.5 (n = 11), and those with an EDSS score of 6 (n = 15).
Overall mean times for the four groups were 8.0, 8.2, 11.1, and 11.6 seconds, respectively. Controls did not differ from people with MS without mobility problems (ie, those with an EDSS score of 0–3.5), but did differ from the other two groups.
“Individuals with MS and no mobility problems have ... very little increase in time due to the addition of cognitive tasks to the TUG test. The two more severe groups perform similarly to each other, with a steeper increase in time to perform the test when the cognitive demand increases,” the researchers said. “Although we cannot automatically generalize the results to more complex everyday activities, such as walking or driving a car while talking on a cell phone, the reduction in performance is an important issue that should be discussed with the patient and his or her caregiver.”
—Jake Remaly
Suggested Reading
Ciol MA, Matsuda PN, Khurana SR, et al. Effect of cognitive demand on functional mobility in ambulatory individuals with multiple sclerosis. Int J MS Care. 2017;19(4):217-224.
Patients with multiple sclerosis (MS) with an Expanded Disability Status Scale (EDSS) score between 4 and 6 have significantly slower times on the Timed Up and Go (TUG) test with the addition of a simple cognitive task, according to research published in the July–August issue of International Journal of MS Care. This reduction in performance “might have implications for a person’s more complex everyday activities,” the researchers said.
Patients with MS may develop cognitive impairment (eg, reduced processing speed or working memory), but standard cognitive assessments overlook how cognitive function affects mobility. To assess how the addition of a cognitive task affects mobility in patients with MS, George H. Kraft, MD, Emeritus Alvord Professor of MS Research at the University of Washington in Seattle, and colleagues conducted a study that included 52 adults with MS and 57 healthy controls. Participants had a mean age of about 47, and most were women.
The participants completed three versions of the TUG test: the standard test, the test plus reciting the alphabet, and the test plus subtracting from a number by threes. Times to complete the tests were compared between controls and three groups of participants with MS—those with an EDSS score of 0–3.5 (n = 26), those with an EDSS score of 4.0–5.5 (n = 11), and those with an EDSS score of 6 (n = 15).
Overall mean times for the four groups were 8.0, 8.2, 11.1, and 11.6 seconds, respectively. Controls did not differ from people with MS without mobility problems (ie, those with an EDSS score of 0–3.5), but did differ from the other two groups.
“Individuals with MS and no mobility problems have ... very little increase in time due to the addition of cognitive tasks to the TUG test. The two more severe groups perform similarly to each other, with a steeper increase in time to perform the test when the cognitive demand increases,” the researchers said. “Although we cannot automatically generalize the results to more complex everyday activities, such as walking or driving a car while talking on a cell phone, the reduction in performance is an important issue that should be discussed with the patient and his or her caregiver.”
—Jake Remaly
Suggested Reading
Ciol MA, Matsuda PN, Khurana SR, et al. Effect of cognitive demand on functional mobility in ambulatory individuals with multiple sclerosis. Int J MS Care. 2017;19(4):217-224.
Opioid management protocol lowered trauma patient pain medication use
BALTIMORE – A pain management protocol implemented in a trauma service reduced opioid intake in trauma patients while improving patient satisfaction, according to a retrospective study.
The opioid epidemic continues to grow every day, partly as a result of irresponsible overprescribing of opioid medication, according to Jessica Gross, MB BAO BCh, FACS, a trauma surgeon from Wake Forest (N.C.) Baptist Health at the American Association for the Surgery of Trauma annual meeting. Dr. Gross and her colleagues developed a pain management protocol (PMP) to provide adequate pain control while using fewer opioids in the postdischarge setting. They tested their PMP through a retrospective chart review of 498 patients admitted to the trauma service between January 2015 and December 2016, half of which were admitted before the PMP was initiated and half of which were admitted afterward.
The PMP involved a stepped approach to treating pain, with acetaminophen or ibuprofen as needed for mild pain, one 5-mg tablet of oxycodone/acetaminophen every 6 hours for moderate pain, two tablets for severe pain, and 50-100 mg of tramadol every 6 hours for breakthrough pain.
Counseling services for patients who were found to be in danger of substance use were provided in the hospital, and at discharge, patients received a weaning plan for their medication, according to Dr. Gross.
If the short-acting medications were found to be inadequate to control pain, patients were given slow-release pain medication as needed.
Average total medication, including at discharge and for refills, prescribed after PMP initiation was 1,242 morphine milligram equivalents (MME), compared with 2,421 MME prior to the protocol (P less than .0001).
After the protocol was implemented, Dr. Gross and her colleagues found the number of patients prescribed a refill dropped from 39.7% to 28.1%, with the size of those refills dropping from 1,032 MME to 213 MME on average.
“By having a comprehensive pain management protocol, we can reduce the amount of pain medications we prescribe for outpatient use, from discharge from the trauma service,” said Dr. Gross. “Additionally, we have shown that by having a protocol in place, we not only decreased the number of refills we were providing, but also the amount of pain medications that was prescribed within these refills.”
Through a Press Ganey survey analysis of patients during the month before and the month after the PMP implementation, investigators found a significant increase in patient satisfaction and overall pain management, according to Dr. Gross,
In addition, the main trauma floor where the PMP was implemented was recognized for the most improvement in overall hospital rating and pain management, compared with the previous year.
Discussant Oscar Guillamondegui MD,FACS, medical director of the trauma ICU at Vanderbilt University, Nashville, Tenn., acknowledged the importance of PMPs and the work investigators presented.
“I would consider this the next generation of ERAS [enhanced recovery after surgery], or ERAT [enhanced recovery after trauma] in pain perception modification,” said Dr. Guillamondegui. “Dr. Gross and the multidisciplinary group at Wake Forest have provided compelling evidence to help alleviate [the opioid epidemic].”
In a question-and-answer session following the presentation, attendees voiced concern over how a PMP would be used among patients who are more familiar with hospital systems, in particular concerning self-reported pain levels.
“Most of us employed at acute care centers are not working in utopia. Many of our patients are heroin addicts, are very bright, and know how to identify 10 on those silly smiley faces so that they get more medicine,” said Charles Lucas, MD, FACS, professor of surgeon at Wayne State University, Detroit. Dr. Lucas also pointed out that even when patients report false levels of pain, doctors still are required to put it into the electronic medical record for fear of repercussions,
In response, Dr. Gross said doctors on the floor reviewed patients to make sure they were receiving all doses of pain medications. If doctors felt the patient’s pain regimen was adequate, despite the patient reporting otherwise, no changes were made.
Certain limitations include not being able to confirm whether patients received prescription medication elsewhere, nor any concrete data on patient satisfaction after discharge other than an inference based on fewer refills and lower refill MME.
Investigators reported no relevant financial disclosures.
[email protected]
On Twitter @eaztweets
BALTIMORE – A pain management protocol implemented in a trauma service reduced opioid intake in trauma patients while improving patient satisfaction, according to a retrospective study.
The opioid epidemic continues to grow every day, partly as a result of irresponsible overprescribing of opioid medication, according to Jessica Gross, MB BAO BCh, FACS, a trauma surgeon from Wake Forest (N.C.) Baptist Health at the American Association for the Surgery of Trauma annual meeting. Dr. Gross and her colleagues developed a pain management protocol (PMP) to provide adequate pain control while using fewer opioids in the postdischarge setting. They tested their PMP through a retrospective chart review of 498 patients admitted to the trauma service between January 2015 and December 2016, half of which were admitted before the PMP was initiated and half of which were admitted afterward.
The PMP involved a stepped approach to treating pain, with acetaminophen or ibuprofen as needed for mild pain, one 5-mg tablet of oxycodone/acetaminophen every 6 hours for moderate pain, two tablets for severe pain, and 50-100 mg of tramadol every 6 hours for breakthrough pain.
Counseling services for patients who were found to be in danger of substance use were provided in the hospital, and at discharge, patients received a weaning plan for their medication, according to Dr. Gross.
If the short-acting medications were found to be inadequate to control pain, patients were given slow-release pain medication as needed.
Average total medication, including at discharge and for refills, prescribed after PMP initiation was 1,242 morphine milligram equivalents (MME), compared with 2,421 MME prior to the protocol (P less than .0001).
After the protocol was implemented, Dr. Gross and her colleagues found the number of patients prescribed a refill dropped from 39.7% to 28.1%, with the size of those refills dropping from 1,032 MME to 213 MME on average.
“By having a comprehensive pain management protocol, we can reduce the amount of pain medications we prescribe for outpatient use, from discharge from the trauma service,” said Dr. Gross. “Additionally, we have shown that by having a protocol in place, we not only decreased the number of refills we were providing, but also the amount of pain medications that was prescribed within these refills.”
Through a Press Ganey survey analysis of patients during the month before and the month after the PMP implementation, investigators found a significant increase in patient satisfaction and overall pain management, according to Dr. Gross,
In addition, the main trauma floor where the PMP was implemented was recognized for the most improvement in overall hospital rating and pain management, compared with the previous year.
Discussant Oscar Guillamondegui MD,FACS, medical director of the trauma ICU at Vanderbilt University, Nashville, Tenn., acknowledged the importance of PMPs and the work investigators presented.
“I would consider this the next generation of ERAS [enhanced recovery after surgery], or ERAT [enhanced recovery after trauma] in pain perception modification,” said Dr. Guillamondegui. “Dr. Gross and the multidisciplinary group at Wake Forest have provided compelling evidence to help alleviate [the opioid epidemic].”
In a question-and-answer session following the presentation, attendees voiced concern over how a PMP would be used among patients who are more familiar with hospital systems, in particular concerning self-reported pain levels.
“Most of us employed at acute care centers are not working in utopia. Many of our patients are heroin addicts, are very bright, and know how to identify 10 on those silly smiley faces so that they get more medicine,” said Charles Lucas, MD, FACS, professor of surgeon at Wayne State University, Detroit. Dr. Lucas also pointed out that even when patients report false levels of pain, doctors still are required to put it into the electronic medical record for fear of repercussions,
In response, Dr. Gross said doctors on the floor reviewed patients to make sure they were receiving all doses of pain medications. If doctors felt the patient’s pain regimen was adequate, despite the patient reporting otherwise, no changes were made.
Certain limitations include not being able to confirm whether patients received prescription medication elsewhere, nor any concrete data on patient satisfaction after discharge other than an inference based on fewer refills and lower refill MME.
Investigators reported no relevant financial disclosures.
[email protected]
On Twitter @eaztweets
BALTIMORE – A pain management protocol implemented in a trauma service reduced opioid intake in trauma patients while improving patient satisfaction, according to a retrospective study.
The opioid epidemic continues to grow every day, partly as a result of irresponsible overprescribing of opioid medication, according to Jessica Gross, MB BAO BCh, FACS, a trauma surgeon from Wake Forest (N.C.) Baptist Health at the American Association for the Surgery of Trauma annual meeting. Dr. Gross and her colleagues developed a pain management protocol (PMP) to provide adequate pain control while using fewer opioids in the postdischarge setting. They tested their PMP through a retrospective chart review of 498 patients admitted to the trauma service between January 2015 and December 2016, half of which were admitted before the PMP was initiated and half of which were admitted afterward.
The PMP involved a stepped approach to treating pain, with acetaminophen or ibuprofen as needed for mild pain, one 5-mg tablet of oxycodone/acetaminophen every 6 hours for moderate pain, two tablets for severe pain, and 50-100 mg of tramadol every 6 hours for breakthrough pain.
Counseling services for patients who were found to be in danger of substance use were provided in the hospital, and at discharge, patients received a weaning plan for their medication, according to Dr. Gross.
If the short-acting medications were found to be inadequate to control pain, patients were given slow-release pain medication as needed.
Average total medication, including at discharge and for refills, prescribed after PMP initiation was 1,242 morphine milligram equivalents (MME), compared with 2,421 MME prior to the protocol (P less than .0001).
After the protocol was implemented, Dr. Gross and her colleagues found the number of patients prescribed a refill dropped from 39.7% to 28.1%, with the size of those refills dropping from 1,032 MME to 213 MME on average.
“By having a comprehensive pain management protocol, we can reduce the amount of pain medications we prescribe for outpatient use, from discharge from the trauma service,” said Dr. Gross. “Additionally, we have shown that by having a protocol in place, we not only decreased the number of refills we were providing, but also the amount of pain medications that was prescribed within these refills.”
Through a Press Ganey survey analysis of patients during the month before and the month after the PMP implementation, investigators found a significant increase in patient satisfaction and overall pain management, according to Dr. Gross,
In addition, the main trauma floor where the PMP was implemented was recognized for the most improvement in overall hospital rating and pain management, compared with the previous year.
Discussant Oscar Guillamondegui MD,FACS, medical director of the trauma ICU at Vanderbilt University, Nashville, Tenn., acknowledged the importance of PMPs and the work investigators presented.
“I would consider this the next generation of ERAS [enhanced recovery after surgery], or ERAT [enhanced recovery after trauma] in pain perception modification,” said Dr. Guillamondegui. “Dr. Gross and the multidisciplinary group at Wake Forest have provided compelling evidence to help alleviate [the opioid epidemic].”
In a question-and-answer session following the presentation, attendees voiced concern over how a PMP would be used among patients who are more familiar with hospital systems, in particular concerning self-reported pain levels.
“Most of us employed at acute care centers are not working in utopia. Many of our patients are heroin addicts, are very bright, and know how to identify 10 on those silly smiley faces so that they get more medicine,” said Charles Lucas, MD, FACS, professor of surgeon at Wayne State University, Detroit. Dr. Lucas also pointed out that even when patients report false levels of pain, doctors still are required to put it into the electronic medical record for fear of repercussions,
In response, Dr. Gross said doctors on the floor reviewed patients to make sure they were receiving all doses of pain medications. If doctors felt the patient’s pain regimen was adequate, despite the patient reporting otherwise, no changes were made.
Certain limitations include not being able to confirm whether patients received prescription medication elsewhere, nor any concrete data on patient satisfaction after discharge other than an inference based on fewer refills and lower refill MME.
Investigators reported no relevant financial disclosures.
[email protected]
On Twitter @eaztweets
AT THE AAST ANNUAL MEETING
Key clinical point:
Major finding: Average prescription fell to 1,242 morphine milligram equivalents (MME) per prescription, compared with 2,421 MME per prescription prior to the protocol.
Data Source: Retrospective chart review of 498 trauma patients from Jan. 1, 2015, and Dec. 31, 2016.
Disclosures: Investigators reported no relevant financial disclosures.
New and Noteworthy Information—October 2017
Is Vitamin D Deficiency a Risk Factor for MS?
Vitamin D deficiency is a risk factor for multiple sclerosis (MS), according to a study published online ahead of print September 13 in Neurology. Researchers conducted a prospective nested case-control study among more than 800,000 women in the Finnish Maternity Cohort who had blood samples taken during pregnancy. Investigators identified 1,092 women with MS diagnosed an average of nine years after giving the blood samples. Researchers compared their vitamin D levels with those of 2,123 women who did not develop MS. Each 50 nmol/L increase in vitamin D levels in the blood was associated with a 39% reduced risk of developing MS. In addition, women who had deficient levels of vitamin D (ie, < 30 nmol/L) had a 43% higher risk of MS, compared with women who had adequate levels of vitamin D (ie, ≥ 50 nmol/L).
Munger KL, Hongell K, Åivo J, et al. 25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort. Neurology. 2017 Sep 13 [Epub ahead of print].
Can Eye Changes Signal Frontotemporal Degeneration?
Frontotemporal degeneration (FTD) is associated with outer retina thinning, and this thinning correlates with disease severity, according to a cross-sectional study published online ahead of print September 8 in Neurology. Researchers examined retinal structure using standard spectral-domain optical coherence tomography in 38 consecutively enrolled patients with FTD and 44 controls. The researchers excluded patients with presumed Alzheimer’s disease, eyes with poor image quality, or confounding diseases. Adjusting for age, sex, and race, patients with FTD had a thinner outer retina, compared with controls. Patients with FTD also had a thinner outer nuclear layer and ellipsoid zone, compared with controls. The groups had similar thicknesses for inner retinal layers.
Kim BJ, Irwin DJ, Song D, et al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology. 2017 Sep 8 [Epub ahead of print].
A New Diagnostic Test for Alzheimer’s Disease
Blood sample analysis may help diagnose Alzheimer’s disease and distinguish between different types of neurodegenerative disorders, according to a study published online ahead of print September 5 in the Proceedings of the National Academy of Sciences. Investigators used attenuated total reflection FTIR spectroscopy combined with chemometric techniques to analyze blood plasma samples from 347 participants with neurodegenerative diseases and 202 age-matched healthy individuals. Alzheimer’s disease (n = 164) was identified with 70% sensitivity and specificity, which after the incorporation of APOE ε4 information, increased to 86% when individuals carried one or two alleles of ε4, and to 72% sensitivity and 77% specificity when individuals did not carry ε4 alleles. The test segregated Alzheimer’s disease from dementia with Lewy bodies (n = 34) with 90% sensitivity and specificity.
Paraskevaidi M, Morais CLM, Lima KMG, et al. Differential diagnosis of Alzheimer’s disease using spectrochemical analysis of blood. Proc Natl Acad Sci U S A. 2017 Sep 5 [Epub ahead of print].
New Indication for Briviact CV
The FDA has approved a supplemental new drug application for Briviact (brivaracetam) CV as monotherapy for partial-onset seizures in patients age 16 and older with epilepsy. Briviact previously was approved as adjunctive treatment for partial-onset seizures in this age group. UCB, which markets Briviact, applied for the monotherapy indication after the FDA advised that it is acceptable to extrapolate the efficacy and safety of drugs approved as adjunctive therapy for the treatment of partial-onset seizures to their use as monotherapy for the treatment of partial-onset seizures. Gradual dose escalation is not required when initiating treatment with Briviact for monotherapy or adjunctive therapy, which allows clinicians to initiate treatment at a therapeutic dose. Briviact formulations include film-coated tablets, oral solution, and injection. UCB is headquartered in Brussels.
Less REM Sleep Is Associated With Greater Dementia Risk
REM sleep may be associated with risk of dementia, according to a study published online ahead of print August 23 in Neurology. Researchers examined associations between sleep architecture and the prospective risk of incident dementia in a subset of 321 Framingham Heart Study Offspring participants who participated in the Sleep Heart Health Study between 1995 and 1998, and were older than 60 at the time of sleep assessment (mean age, 67; 50% male). Stages of sleep were quantified using home-based polysomnography. Participants were followed for up to 19 years for incident dementia. Researchers observed 32 cases of incident dementia. Each percentage reduction in REM sleep was associated with an approximately 9% increase in the risk of incident dementia (hazard ratio, 0.91).
Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017 Aug 23 [Epub ahead of print].
Mononucleosis May Increase Risk of MS
Epstein-Barr nuclear antigen-1 seropositivty is independently associated with increased risk of multiple sclerosis (MS) or clinically isolated syndrome (CIS), according to a study published online ahead of print August 30 in Neurology. Researchers recruited 1,090 black, Hispanic, and white people with MS or CIS and matched controls over a three-year period. Participants were tested for the Epstein-Barr virus antibody and were asked whether they had ever had mononucleosis. Blacks who had had mononucleosis were more than four times more likely to develop MS, compared with those who had not had mononucleosis. Hispanics and whites who had had mononucleosis were nearly four times and two times, respectively, more likely to develop MS or CIS, compared with those who had not had mononucleosis.
Langer-Gould A, Wu J, Lucas R, et al. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: a multiethnic study. Neurology. 2017 Aug 30 [Epub ahead of print].
Asthma Medicine May Decrease Risk of Parkinson’s Disease
Salbutamol, a brain-penetrant asthma medication, is associated with reduced risk of Parkinson’s disease, according to a study published September 1 in Science. Researchers used an unbiased screen targeting endogenous gene expression to discover that the β2-adrenoreceptor (β2AR) is a regulator of the α-synuclein gene. Research has indicated that excess production of α-synuclein may be a causative factor in Parkinson’s disease. Over 11 years of follow-up in four million Norwegians, the β2AR agonist salbutamol was associated with reduced risk of Parkinson’s disease (rate ratio, 0.66). A β2AR antagonist correlated with increased risk.
Mittal S, Bjørnevik K, Im DS, et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891-898 [Epub ahead of print].
Odds of Developing Alzheimer’s Disease Same for Men and Women With APOE Genotype
Men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing Alzheimer’s disease from age 55 to 85, but women have an increased risk at younger ages, according to a study published online ahead of print August 28 in JAMA Neurology. Researchers analyzed data from 27 studies with nearly 58,000 participants. Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Age-adjusted odds ratios and 95% confidence intervals for developing mild cognitive impairment and Alzheimer’s disease were calculated for men and women across APOE genotypes. Men and women with the APOE ε3/ε4 genotype from ages 55 to 85 did not show a difference in Alzheimer’s disease risk. Women had an increased risk of Alzheimer’s disease compared with men between the ages of 65 and 75.
Neu SC, Pa J, Kukull W, et al. Apolipoprotein e genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017 Aug 28 [Epub ahead of print].
Does Dimethyl Fumarate Prevent MS Reactivation After Natalizumab Discontinuation?
Dimethyl fumarate appears generally safe and may be a promising drug for patients at high risk of progressive multifocal leukoencephalopathy (PML) who discontinue natalizumab, according to an article published online ahead of print August 26 in the Journal of Neurology, Neurosurgery and Psychiatry. Thirty-nine patients with relapsing-remitting multiple sclerosis (MS) at high risk of PML were switched from natalizumab to dimethyl fumarate and underwent neurologic and 3T MRI monitoring for two years. Clinical and MRI data regarding the two-year period preceding natalizumab treatment, the two years of natalizumab treatment, and the two years of dimethyl fumarate treatment were collected. During the dimethyl fumarate phase, one or more relapses occurred in five patients (12.8%), increased disability progression occurred in four patients (10.3%), and MRI activity occurred in eight patients (20.5%). Post-natalizumab rebound effect was observed in one patient. Almost 80% of the patients had no evidence of disease activity after two years of dimethyl fumarate treatment. No carryover PML among investigated cases was observed.
Calabrese M, Pitteri M, Farina G, et al. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. J Neurol Neurosurg Psychiatry. 2017 Aug 26 [Epub ahead of print].
Austedo Approved for Treatment of Tardive Dyskinesia in Adults
The FDA has approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. The approval was based on results from two phase III randomized, double-blind, placebo-controlled, parallel group studies assessing the efficacy and safety of Austedo in reducing the severity of abnormal involuntary movements associated with tardive dyskinesia. Austedo was previously approved in April for the treatment of chorea associated with Huntington’s disease. The most common adverse reactions (ie, 4% of Austedo-treated patients and greater than placebo) in controlled clinical studies of patients with tardive dyskinesia were nasopharyngitis and insomnia. Teva Pharmaceutical Industries, which markets Austedo, is headquartered in Jerusalem.
Orphan Drug Designation Granted for EPX-300
The FDA has granted Orphan Drug Designation for EPX-300 for the treatment of patients with Dravet syndrome. EPX-300 is a repurposed antidepressant that acts via modulation of serotonin signaling pathways. Researchers discovered its potential as a treatment for patients with Dravet syndrome using a phenotype-based zebrafish drug screening platform. Using the zebrafish model for Dravet syndrome, investigators identified drug candidates from a screen of more than 3,000 drugs that suppress seizures and other symptoms associated with neurologic diseases. Epygenix Therapeutics, which is developing EPX-300, is headquartered in Paramus, New Jersey.
FDA Approves Expanded Indication for Aptiom
The FDA has approved a supplemental new drug application to expand the indication for Aptiom (eslicarbazepine acetate) to include treatment of partial-onset seizures in children age 4 to 17. The safety and efficacy of Aptiom as monotherapy and adjunctive therapy for the treatment of partial-onset seizures in adults was established in five multicenter, randomized, controlled clinical trials. Data from three clinical trials supported the safety and tolerability of Aptiom for the treatment of partial-onset seizures in pediatric patients. Pharmacokinetic analyses of adult and pediatric data supported its use in the pediatric population. Aptiom is a once-daily, immediate release drug that can be taken whole or crushed, with or without food. Sunovion Pharmaceuticals, which markets Aptiom, is headquartered in Marlborough, Massachusetts.
—Kimberly Williams
Is Vitamin D Deficiency a Risk Factor for MS?
Vitamin D deficiency is a risk factor for multiple sclerosis (MS), according to a study published online ahead of print September 13 in Neurology. Researchers conducted a prospective nested case-control study among more than 800,000 women in the Finnish Maternity Cohort who had blood samples taken during pregnancy. Investigators identified 1,092 women with MS diagnosed an average of nine years after giving the blood samples. Researchers compared their vitamin D levels with those of 2,123 women who did not develop MS. Each 50 nmol/L increase in vitamin D levels in the blood was associated with a 39% reduced risk of developing MS. In addition, women who had deficient levels of vitamin D (ie, < 30 nmol/L) had a 43% higher risk of MS, compared with women who had adequate levels of vitamin D (ie, ≥ 50 nmol/L).
Munger KL, Hongell K, Åivo J, et al. 25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort. Neurology. 2017 Sep 13 [Epub ahead of print].
Can Eye Changes Signal Frontotemporal Degeneration?
Frontotemporal degeneration (FTD) is associated with outer retina thinning, and this thinning correlates with disease severity, according to a cross-sectional study published online ahead of print September 8 in Neurology. Researchers examined retinal structure using standard spectral-domain optical coherence tomography in 38 consecutively enrolled patients with FTD and 44 controls. The researchers excluded patients with presumed Alzheimer’s disease, eyes with poor image quality, or confounding diseases. Adjusting for age, sex, and race, patients with FTD had a thinner outer retina, compared with controls. Patients with FTD also had a thinner outer nuclear layer and ellipsoid zone, compared with controls. The groups had similar thicknesses for inner retinal layers.
Kim BJ, Irwin DJ, Song D, et al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology. 2017 Sep 8 [Epub ahead of print].
A New Diagnostic Test for Alzheimer’s Disease
Blood sample analysis may help diagnose Alzheimer’s disease and distinguish between different types of neurodegenerative disorders, according to a study published online ahead of print September 5 in the Proceedings of the National Academy of Sciences. Investigators used attenuated total reflection FTIR spectroscopy combined with chemometric techniques to analyze blood plasma samples from 347 participants with neurodegenerative diseases and 202 age-matched healthy individuals. Alzheimer’s disease (n = 164) was identified with 70% sensitivity and specificity, which after the incorporation of APOE ε4 information, increased to 86% when individuals carried one or two alleles of ε4, and to 72% sensitivity and 77% specificity when individuals did not carry ε4 alleles. The test segregated Alzheimer’s disease from dementia with Lewy bodies (n = 34) with 90% sensitivity and specificity.
Paraskevaidi M, Morais CLM, Lima KMG, et al. Differential diagnosis of Alzheimer’s disease using spectrochemical analysis of blood. Proc Natl Acad Sci U S A. 2017 Sep 5 [Epub ahead of print].
New Indication for Briviact CV
The FDA has approved a supplemental new drug application for Briviact (brivaracetam) CV as monotherapy for partial-onset seizures in patients age 16 and older with epilepsy. Briviact previously was approved as adjunctive treatment for partial-onset seizures in this age group. UCB, which markets Briviact, applied for the monotherapy indication after the FDA advised that it is acceptable to extrapolate the efficacy and safety of drugs approved as adjunctive therapy for the treatment of partial-onset seizures to their use as monotherapy for the treatment of partial-onset seizures. Gradual dose escalation is not required when initiating treatment with Briviact for monotherapy or adjunctive therapy, which allows clinicians to initiate treatment at a therapeutic dose. Briviact formulations include film-coated tablets, oral solution, and injection. UCB is headquartered in Brussels.
Less REM Sleep Is Associated With Greater Dementia Risk
REM sleep may be associated with risk of dementia, according to a study published online ahead of print August 23 in Neurology. Researchers examined associations between sleep architecture and the prospective risk of incident dementia in a subset of 321 Framingham Heart Study Offspring participants who participated in the Sleep Heart Health Study between 1995 and 1998, and were older than 60 at the time of sleep assessment (mean age, 67; 50% male). Stages of sleep were quantified using home-based polysomnography. Participants were followed for up to 19 years for incident dementia. Researchers observed 32 cases of incident dementia. Each percentage reduction in REM sleep was associated with an approximately 9% increase in the risk of incident dementia (hazard ratio, 0.91).
Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017 Aug 23 [Epub ahead of print].
Mononucleosis May Increase Risk of MS
Epstein-Barr nuclear antigen-1 seropositivty is independently associated with increased risk of multiple sclerosis (MS) or clinically isolated syndrome (CIS), according to a study published online ahead of print August 30 in Neurology. Researchers recruited 1,090 black, Hispanic, and white people with MS or CIS and matched controls over a three-year period. Participants were tested for the Epstein-Barr virus antibody and were asked whether they had ever had mononucleosis. Blacks who had had mononucleosis were more than four times more likely to develop MS, compared with those who had not had mononucleosis. Hispanics and whites who had had mononucleosis were nearly four times and two times, respectively, more likely to develop MS or CIS, compared with those who had not had mononucleosis.
Langer-Gould A, Wu J, Lucas R, et al. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: a multiethnic study. Neurology. 2017 Aug 30 [Epub ahead of print].
Asthma Medicine May Decrease Risk of Parkinson’s Disease
Salbutamol, a brain-penetrant asthma medication, is associated with reduced risk of Parkinson’s disease, according to a study published September 1 in Science. Researchers used an unbiased screen targeting endogenous gene expression to discover that the β2-adrenoreceptor (β2AR) is a regulator of the α-synuclein gene. Research has indicated that excess production of α-synuclein may be a causative factor in Parkinson’s disease. Over 11 years of follow-up in four million Norwegians, the β2AR agonist salbutamol was associated with reduced risk of Parkinson’s disease (rate ratio, 0.66). A β2AR antagonist correlated with increased risk.
Mittal S, Bjørnevik K, Im DS, et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891-898 [Epub ahead of print].
Odds of Developing Alzheimer’s Disease Same for Men and Women With APOE Genotype
Men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing Alzheimer’s disease from age 55 to 85, but women have an increased risk at younger ages, according to a study published online ahead of print August 28 in JAMA Neurology. Researchers analyzed data from 27 studies with nearly 58,000 participants. Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Age-adjusted odds ratios and 95% confidence intervals for developing mild cognitive impairment and Alzheimer’s disease were calculated for men and women across APOE genotypes. Men and women with the APOE ε3/ε4 genotype from ages 55 to 85 did not show a difference in Alzheimer’s disease risk. Women had an increased risk of Alzheimer’s disease compared with men between the ages of 65 and 75.
Neu SC, Pa J, Kukull W, et al. Apolipoprotein e genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017 Aug 28 [Epub ahead of print].
Does Dimethyl Fumarate Prevent MS Reactivation After Natalizumab Discontinuation?
Dimethyl fumarate appears generally safe and may be a promising drug for patients at high risk of progressive multifocal leukoencephalopathy (PML) who discontinue natalizumab, according to an article published online ahead of print August 26 in the Journal of Neurology, Neurosurgery and Psychiatry. Thirty-nine patients with relapsing-remitting multiple sclerosis (MS) at high risk of PML were switched from natalizumab to dimethyl fumarate and underwent neurologic and 3T MRI monitoring for two years. Clinical and MRI data regarding the two-year period preceding natalizumab treatment, the two years of natalizumab treatment, and the two years of dimethyl fumarate treatment were collected. During the dimethyl fumarate phase, one or more relapses occurred in five patients (12.8%), increased disability progression occurred in four patients (10.3%), and MRI activity occurred in eight patients (20.5%). Post-natalizumab rebound effect was observed in one patient. Almost 80% of the patients had no evidence of disease activity after two years of dimethyl fumarate treatment. No carryover PML among investigated cases was observed.
Calabrese M, Pitteri M, Farina G, et al. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. J Neurol Neurosurg Psychiatry. 2017 Aug 26 [Epub ahead of print].
Austedo Approved for Treatment of Tardive Dyskinesia in Adults
The FDA has approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. The approval was based on results from two phase III randomized, double-blind, placebo-controlled, parallel group studies assessing the efficacy and safety of Austedo in reducing the severity of abnormal involuntary movements associated with tardive dyskinesia. Austedo was previously approved in April for the treatment of chorea associated with Huntington’s disease. The most common adverse reactions (ie, 4% of Austedo-treated patients and greater than placebo) in controlled clinical studies of patients with tardive dyskinesia were nasopharyngitis and insomnia. Teva Pharmaceutical Industries, which markets Austedo, is headquartered in Jerusalem.
Orphan Drug Designation Granted for EPX-300
The FDA has granted Orphan Drug Designation for EPX-300 for the treatment of patients with Dravet syndrome. EPX-300 is a repurposed antidepressant that acts via modulation of serotonin signaling pathways. Researchers discovered its potential as a treatment for patients with Dravet syndrome using a phenotype-based zebrafish drug screening platform. Using the zebrafish model for Dravet syndrome, investigators identified drug candidates from a screen of more than 3,000 drugs that suppress seizures and other symptoms associated with neurologic diseases. Epygenix Therapeutics, which is developing EPX-300, is headquartered in Paramus, New Jersey.
FDA Approves Expanded Indication for Aptiom
The FDA has approved a supplemental new drug application to expand the indication for Aptiom (eslicarbazepine acetate) to include treatment of partial-onset seizures in children age 4 to 17. The safety and efficacy of Aptiom as monotherapy and adjunctive therapy for the treatment of partial-onset seizures in adults was established in five multicenter, randomized, controlled clinical trials. Data from three clinical trials supported the safety and tolerability of Aptiom for the treatment of partial-onset seizures in pediatric patients. Pharmacokinetic analyses of adult and pediatric data supported its use in the pediatric population. Aptiom is a once-daily, immediate release drug that can be taken whole or crushed, with or without food. Sunovion Pharmaceuticals, which markets Aptiom, is headquartered in Marlborough, Massachusetts.
—Kimberly Williams
Is Vitamin D Deficiency a Risk Factor for MS?
Vitamin D deficiency is a risk factor for multiple sclerosis (MS), according to a study published online ahead of print September 13 in Neurology. Researchers conducted a prospective nested case-control study among more than 800,000 women in the Finnish Maternity Cohort who had blood samples taken during pregnancy. Investigators identified 1,092 women with MS diagnosed an average of nine years after giving the blood samples. Researchers compared their vitamin D levels with those of 2,123 women who did not develop MS. Each 50 nmol/L increase in vitamin D levels in the blood was associated with a 39% reduced risk of developing MS. In addition, women who had deficient levels of vitamin D (ie, < 30 nmol/L) had a 43% higher risk of MS, compared with women who had adequate levels of vitamin D (ie, ≥ 50 nmol/L).
Munger KL, Hongell K, Åivo J, et al. 25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort. Neurology. 2017 Sep 13 [Epub ahead of print].
Can Eye Changes Signal Frontotemporal Degeneration?
Frontotemporal degeneration (FTD) is associated with outer retina thinning, and this thinning correlates with disease severity, according to a cross-sectional study published online ahead of print September 8 in Neurology. Researchers examined retinal structure using standard spectral-domain optical coherence tomography in 38 consecutively enrolled patients with FTD and 44 controls. The researchers excluded patients with presumed Alzheimer’s disease, eyes with poor image quality, or confounding diseases. Adjusting for age, sex, and race, patients with FTD had a thinner outer retina, compared with controls. Patients with FTD also had a thinner outer nuclear layer and ellipsoid zone, compared with controls. The groups had similar thicknesses for inner retinal layers.
Kim BJ, Irwin DJ, Song D, et al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology. 2017 Sep 8 [Epub ahead of print].
A New Diagnostic Test for Alzheimer’s Disease
Blood sample analysis may help diagnose Alzheimer’s disease and distinguish between different types of neurodegenerative disorders, according to a study published online ahead of print September 5 in the Proceedings of the National Academy of Sciences. Investigators used attenuated total reflection FTIR spectroscopy combined with chemometric techniques to analyze blood plasma samples from 347 participants with neurodegenerative diseases and 202 age-matched healthy individuals. Alzheimer’s disease (n = 164) was identified with 70% sensitivity and specificity, which after the incorporation of APOE ε4 information, increased to 86% when individuals carried one or two alleles of ε4, and to 72% sensitivity and 77% specificity when individuals did not carry ε4 alleles. The test segregated Alzheimer’s disease from dementia with Lewy bodies (n = 34) with 90% sensitivity and specificity.
Paraskevaidi M, Morais CLM, Lima KMG, et al. Differential diagnosis of Alzheimer’s disease using spectrochemical analysis of blood. Proc Natl Acad Sci U S A. 2017 Sep 5 [Epub ahead of print].
New Indication for Briviact CV
The FDA has approved a supplemental new drug application for Briviact (brivaracetam) CV as monotherapy for partial-onset seizures in patients age 16 and older with epilepsy. Briviact previously was approved as adjunctive treatment for partial-onset seizures in this age group. UCB, which markets Briviact, applied for the monotherapy indication after the FDA advised that it is acceptable to extrapolate the efficacy and safety of drugs approved as adjunctive therapy for the treatment of partial-onset seizures to their use as monotherapy for the treatment of partial-onset seizures. Gradual dose escalation is not required when initiating treatment with Briviact for monotherapy or adjunctive therapy, which allows clinicians to initiate treatment at a therapeutic dose. Briviact formulations include film-coated tablets, oral solution, and injection. UCB is headquartered in Brussels.
Less REM Sleep Is Associated With Greater Dementia Risk
REM sleep may be associated with risk of dementia, according to a study published online ahead of print August 23 in Neurology. Researchers examined associations between sleep architecture and the prospective risk of incident dementia in a subset of 321 Framingham Heart Study Offspring participants who participated in the Sleep Heart Health Study between 1995 and 1998, and were older than 60 at the time of sleep assessment (mean age, 67; 50% male). Stages of sleep were quantified using home-based polysomnography. Participants were followed for up to 19 years for incident dementia. Researchers observed 32 cases of incident dementia. Each percentage reduction in REM sleep was associated with an approximately 9% increase in the risk of incident dementia (hazard ratio, 0.91).
Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017 Aug 23 [Epub ahead of print].
Mononucleosis May Increase Risk of MS
Epstein-Barr nuclear antigen-1 seropositivty is independently associated with increased risk of multiple sclerosis (MS) or clinically isolated syndrome (CIS), according to a study published online ahead of print August 30 in Neurology. Researchers recruited 1,090 black, Hispanic, and white people with MS or CIS and matched controls over a three-year period. Participants were tested for the Epstein-Barr virus antibody and were asked whether they had ever had mononucleosis. Blacks who had had mononucleosis were more than four times more likely to develop MS, compared with those who had not had mononucleosis. Hispanics and whites who had had mononucleosis were nearly four times and two times, respectively, more likely to develop MS or CIS, compared with those who had not had mononucleosis.
Langer-Gould A, Wu J, Lucas R, et al. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: a multiethnic study. Neurology. 2017 Aug 30 [Epub ahead of print].
Asthma Medicine May Decrease Risk of Parkinson’s Disease
Salbutamol, a brain-penetrant asthma medication, is associated with reduced risk of Parkinson’s disease, according to a study published September 1 in Science. Researchers used an unbiased screen targeting endogenous gene expression to discover that the β2-adrenoreceptor (β2AR) is a regulator of the α-synuclein gene. Research has indicated that excess production of α-synuclein may be a causative factor in Parkinson’s disease. Over 11 years of follow-up in four million Norwegians, the β2AR agonist salbutamol was associated with reduced risk of Parkinson’s disease (rate ratio, 0.66). A β2AR antagonist correlated with increased risk.
Mittal S, Bjørnevik K, Im DS, et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891-898 [Epub ahead of print].
Odds of Developing Alzheimer’s Disease Same for Men and Women With APOE Genotype
Men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing Alzheimer’s disease from age 55 to 85, but women have an increased risk at younger ages, according to a study published online ahead of print August 28 in JAMA Neurology. Researchers analyzed data from 27 studies with nearly 58,000 participants. Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Age-adjusted odds ratios and 95% confidence intervals for developing mild cognitive impairment and Alzheimer’s disease were calculated for men and women across APOE genotypes. Men and women with the APOE ε3/ε4 genotype from ages 55 to 85 did not show a difference in Alzheimer’s disease risk. Women had an increased risk of Alzheimer’s disease compared with men between the ages of 65 and 75.
Neu SC, Pa J, Kukull W, et al. Apolipoprotein e genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017 Aug 28 [Epub ahead of print].
Does Dimethyl Fumarate Prevent MS Reactivation After Natalizumab Discontinuation?
Dimethyl fumarate appears generally safe and may be a promising drug for patients at high risk of progressive multifocal leukoencephalopathy (PML) who discontinue natalizumab, according to an article published online ahead of print August 26 in the Journal of Neurology, Neurosurgery and Psychiatry. Thirty-nine patients with relapsing-remitting multiple sclerosis (MS) at high risk of PML were switched from natalizumab to dimethyl fumarate and underwent neurologic and 3T MRI monitoring for two years. Clinical and MRI data regarding the two-year period preceding natalizumab treatment, the two years of natalizumab treatment, and the two years of dimethyl fumarate treatment were collected. During the dimethyl fumarate phase, one or more relapses occurred in five patients (12.8%), increased disability progression occurred in four patients (10.3%), and MRI activity occurred in eight patients (20.5%). Post-natalizumab rebound effect was observed in one patient. Almost 80% of the patients had no evidence of disease activity after two years of dimethyl fumarate treatment. No carryover PML among investigated cases was observed.
Calabrese M, Pitteri M, Farina G, et al. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events. J Neurol Neurosurg Psychiatry. 2017 Aug 26 [Epub ahead of print].
Austedo Approved for Treatment of Tardive Dyskinesia in Adults
The FDA has approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. The approval was based on results from two phase III randomized, double-blind, placebo-controlled, parallel group studies assessing the efficacy and safety of Austedo in reducing the severity of abnormal involuntary movements associated with tardive dyskinesia. Austedo was previously approved in April for the treatment of chorea associated with Huntington’s disease. The most common adverse reactions (ie, 4% of Austedo-treated patients and greater than placebo) in controlled clinical studies of patients with tardive dyskinesia were nasopharyngitis and insomnia. Teva Pharmaceutical Industries, which markets Austedo, is headquartered in Jerusalem.
Orphan Drug Designation Granted for EPX-300
The FDA has granted Orphan Drug Designation for EPX-300 for the treatment of patients with Dravet syndrome. EPX-300 is a repurposed antidepressant that acts via modulation of serotonin signaling pathways. Researchers discovered its potential as a treatment for patients with Dravet syndrome using a phenotype-based zebrafish drug screening platform. Using the zebrafish model for Dravet syndrome, investigators identified drug candidates from a screen of more than 3,000 drugs that suppress seizures and other symptoms associated with neurologic diseases. Epygenix Therapeutics, which is developing EPX-300, is headquartered in Paramus, New Jersey.
FDA Approves Expanded Indication for Aptiom
The FDA has approved a supplemental new drug application to expand the indication for Aptiom (eslicarbazepine acetate) to include treatment of partial-onset seizures in children age 4 to 17. The safety and efficacy of Aptiom as monotherapy and adjunctive therapy for the treatment of partial-onset seizures in adults was established in five multicenter, randomized, controlled clinical trials. Data from three clinical trials supported the safety and tolerability of Aptiom for the treatment of partial-onset seizures in pediatric patients. Pharmacokinetic analyses of adult and pediatric data supported its use in the pediatric population. Aptiom is a once-daily, immediate release drug that can be taken whole or crushed, with or without food. Sunovion Pharmaceuticals, which markets Aptiom, is headquartered in Marlborough, Massachusetts.
—Kimberly Williams
